Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

Andrea Sottoriva, Inmaculada Spiteri, Sara Piccirillo, Anestis Touloumis, V. Peter Collins, John C. Marioni, Christina Curtis, Colin Watts, Simon Tavaré

Proceedings of the National Academy of Sciences · 2013 · 1.8K citations · 32 references

DOIFull text

Open access

Concepts

TL;DR

Glioblastoma is an aggressive brain cancer with poor prognosis and limited therapies, and intratumor heterogeneity is thought to drive treatment failure, yet its evolutionary extent remains poorly understood. The authors developed a surgical multisampling scheme to collect spatially distinct tumor fragments from 11 GB patients. Integrated genomic analysis of these fragments revealed extensive intratumor heterogeneity, with distinct subtypes and multiple coexisting lineages, and phylogenetic reconstruction identified early EGFR/CDKN2A/B alterations and later PDGFRA/PTEN changes, underscoring patient‑specific evolutionary patterns that may inform treatment design.

Abstract

Glioblastoma (GB) is the most common and aggressive primary brain malignancy, with poor prognosis and a lack of effective therapeutic options. Accumulating evidence suggests that intratumor heterogeneity likely is the key to understanding treatment failure. However, the extent of intratumor heterogeneity as a result of tumor evolution is still poorly understood. To address this, we developed a unique surgical multisampling scheme to collect spatially distinct tumor fragments from 11 GB patients. We present an integrated genomic analysis that uncovers extensive intratumor heterogeneity, with most patients displaying different GB subtypes within the same tumor. Moreover, we reconstructed the phylogeny of the fragments for each patient, identifying copy number alterations in EGFR and CDKN2A/B/p14ARF as early events, and aberrations in PDGFRA and PTEN as later events during cancer progression. We also characterized the clonal organization of each tumor fragment at the single-molecule level, detecting multiple coexisting cell lineages. Our results reveal the genome-wide architecture of intratumor variability in GB across multiple spatial scales and patient-specific patterns of cancer evolution, with consequences for treatment design.

References

32